{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.2","value":"82.85"},{"groupId":"OG001","spread":"50.6","value":"229.4"},{"comment":"Not calculable, insufficient number of participants for calculation after excluding the data impacted by prohibited medication co-administration.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"80.9","value":"590.2"},{"groupId":"OG004","spread":"21.9","value":"677.0"},{"groupId":"OG005","spread":"53.4","value":"358.0"},{"groupId":"OG006","spread":"40.9","value":"717.5"},{"groupId":"OG007","spread":"48.8","value":"613.3"},{"groupId":"OG008","spread":"57.3","value":"819.3"},{"groupId":"OG009","spread":"41.7","value":"716.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"19"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"description":"Maximum observed plasma concentration(ng/mL), at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 50 mg once daily continuously.","id":"OG000","title":"Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 100 mg once daily continuously.","id":"OG001","title":"Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 200 mg once daily continuously.","id":"OG002","title":"Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 300 mg once daily continuously.","id":"OG003","title":"Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received sunvozertinib 400 mg once daily continuously.","id":"OG004","title":"Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.","id":"OG005","title":"Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.","id":"OG006","title":"Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.","id":"OG007","title":"Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"OG008","title":"Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"OG009","title":"Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment.\n\nNo patient was enrolled into this cohort.","id":"OG010","title":"Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who have received at least one dose of study drug with at least one measurable plasma concentration of DZD9008 post dose without any important deviations or events that would exclude the participants.","reportingStatus":"POSTED","timeFrame":"Cycle 2 Day 1: 0 (predose) up to 24 hours (for Part A Dose expansion and expansion)","title":"Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008","type":"SECONDARY","unitOfMeasure":"ng/mL"}